Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osiris trumpets patchy Prochymal heart data, and extend trial duration

This article was originally published in Clinica

Executive Summary

Osiris's off-the-shelf stem cell treatment Prochymal (remestemcel-L) has shown some early promise in preventing heart failure in a Phase II trial in heart attack patients, the company says. But although the trial, with some 220 patients, is one of the largest stem cell studies ever undertaken, the top-line data released by the company are patchy and no figures for the primary endpoint measure of left ventricular end systolic volume have yet been given, clouding the true picture of the product's efficacy in the study until the full data are released.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT099099

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel